The Deterministic Quasi-Chaos of Pharma's Big Data

Me-too drugs and the butterfly effect LONDON, Sept. 17, 2015 /PRNewswire/ — With regulators, Health Technology Assessment agencies and payers demanding demonstrable evidence of value it is becoming increasingly difficult for Pharma to not only get new products approved, but also to negotiate premium reimbursement or ensure continuing reimbursement for licensed brands. Consequently, success of a […]

McCormack Pharma's Landmark Discovery could mean New Guidelines for use of Anti-Platelet Drug

LONDON, April 23, 2015 /PRNewswire/ — Clopidogrel (Plavix) is an anti-platelet drug that is used to prevent the formation of a thrombus (clot) in vulnerable patients. However, a significant proportion of patients who receive clopidogrel remain at risk for subsequent death, myocardial infarction, stent thrombosis, and stroke because of insufficient clopidogrel-induced platelet inhibition. Using customized relational databases […]

McCormack Pharma Announces a Breakthrough Discovery in the Mechanism of Clopidogrel Resistance

LONDON, Nov. 3, 2014 /PRNewswire/ — A landmark discovery by McCormack Pharma provides a new insight into why some patient subgroups are at increased risk of showing resistance to the popular anti-platelet drug clopidogrel (Plavix). Importantly, these ground-breaking findings suggest that at-risk patients can easily be identified by an inexpensive assay; or for expediency, an […]